<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170884">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871910</url>
  </required_header>
  <id_info>
    <org_study_id>P04630</org_study_id>
    <nct_id>NCT00871910</nct_id>
  </id_info>
  <brief_title>Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)</brief_title>
  <official_title>A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Cyclin-Dependent Kinase (CDK) Inhibitor SCH 727965 Administered Every 3 Weeks in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered
      dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour
      intravenous (IV) infusion (Part 1), and as an 8-hour or 24-hour IV infusion (Part 2). Each
      3-week period is considered one treatment cycle. Part 3 of this trial will evaluate the
      effect of coadministration of antiemetic drug aprepitant on the pharmacokinetics of SCH
      727965 administered as a 2 hour IV infusion once every 3 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SCH 727965, including maximum administered dose and dose-limiting toxicity</measure>
    <time_frame>End of trial</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part 1 and Part 2, pharmacodynamic effects of SCH 727965 with an ex vivo lymphocyte stimulation assay of participant's peripheral blood lymphocytes.</measure>
    <time_frame>Cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Part 3, area under the plasma concentration versus time curve and maximum concentration of SCH 727965 administered as a 2 hour intravenous infusion with or without aprepitant in participants with advanced malignancies.</measure>
    <time_frame>Cycle 1 Days 1 and 2, and Cycle 2 Days 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>2 Hour SCH 727965 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 2 hour SCH 727965 IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 Hour SCH 727965 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 8 hour SCH 727965 IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 Hour SCH 727965 infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants treated with 24 hour SCH 727965 IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)</description>
    <arm_group_label>2 Hour SCH 727965 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts</description>
    <arm_group_label>8 Hour SCH 727965 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts</description>
    <arm_group_label>24 Hour SCH 727965 infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCH 727965</intervention_name>
    <description>SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.</description>
    <arm_group_label>2 Hour SCH 727965 infusions plus aprepitant in Cycle 1</arm_group_label>
    <arm_group_label>2 Hour SCH 727965 infusion plus aprepitant in Cycle 2</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;=18 years, either sex, any race.

          -  Subjects must have histologically proven solid tumors, non-Hodgkin's lymphoma, or
             multiple myeloma.

          -  There must be no known standard therapy, or disease must be refractory to standard
             therapy.

          -  Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

          -  Adequate hematologic, renal, and hepatic organ function and laboratory parameters.

        Exclusion Criteria:

          -  Symptomatic brain metastases or primary central nervous system malignancy.

          -  Previous radiation therapy to &gt;25% of the total bone marrow.

          -  Previous treatment with SCH 727965.

          -  Known HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 Dec;70(6):891-8. doi: 10.1007/s00280-012-1967-y. Epub 2012 Oct 9.</citation>
    <PMID>23053255</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 5, 2015</lastchanged_date>
  <firstreceived_date>March 26, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
